Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Leukemia|March 27, 2026
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemiaLoïc Vasseur, Matthieu Duchmann, Nicolas Duployez, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
American Journal of Obstetrics and Gynecology|March 9, 2019
Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive PlacentaSally L Collins, Bahrin Alemdar, Heleen J van Beekhuizen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 StudyRathana Kim, Yves Chalandon, Philippe Rousselot, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Leukemia|April 27, 2022
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemiaBryann Pardieu, Justine Pasanisi, Frank Ling, et al.
Pageof 15